Source comparison
CJC-1295 No DAC vs Sustained-Release Variants: Comparison
The DAC (drug affinity complex) modification extends CJC-1295's half-life from 30 minutes to approximately 6–8 days by binding the peptide to serum albumin. This creates fundamentally different pharmacokinetics and physiological outcomes. Half-Life ~30 minutes
This comparison does not assign a generated winner or score.
- The DAC (drug affinity complex) modification extends CJC-1295's half-life from 30 minutes to approximately 6–8 days by binding the peptide to serum albumin. This creates fundamentally different pharmacokinetics and physiological outcomes.
- Half-Life
- ~30 minutes
- 6–8 days
- No-DAC requires more frequent dosing but preserves natural pulsatility
- Dosing Frequency
- 3–5× weekly
- 1× weekly or bi-weekly
- With-DAC offers convenience; no-DAC offers rhythm preservation
- GH Secretion Pattern
- Pulsatile (2–3× natural peaks)
- Sustained elevation (~50–80% above baseline continuously)
- No-DAC mimics natural physiology; with-DAC creates supra-physiological baseline
- Receptor Sensitivity
- Maintained over time
- Risk of desensitisation after 8–12 weeks
- No-DAC shows no tolerance development in clinical trials up to 16 weeks
- IGF-1 Elevation
- Moderate (30–45% increase during pulses)
- Pronounced (60–90% sustained increase)
- With-DAC produces higher absolute IGF-1 but risks negative feedback over time
- Ideal Use Case
- Replicating natural GH rhythm for recovery and body recomposition
- Maximising anabolic stimulus during mass-building phases
- No-DAC is the better choice for long-term protocols and physiological optimisation
- The bottom line: CJC-1295 with DAC produces more dramatic short-term IGF-1 elevation and is preferred in research contexts prioritising maximum anabolic stimulus over 8–12 weeks. CJC-1295 no DAC produces sustainable, rhythm-preserving GH amplification suitable for extended protocols without tolerance or negative feedback.